176 related articles for article (PubMed ID: 36919725)
21. Long-term outcome of antineutrophil cytoplasmic antibody-associated small vessel vasculitis after renal transplantation.
Marco H; Mirapeix E; Arcos E; Comas J; Ara J; Gil-Vernet S; Puig J; Vinyas O; Perello M; Oppenheimer F; Poveda R; Ibernón M; Díaz M; Ballarin J;
Clin Transplant; 2013; 27(3):338-47. PubMed ID: 23421384
[TBL] [Abstract][Full Text] [Related]
22. Characteristics and Visual Outcome of Refractory Retinal Vasculitis Associated With Antineutrophil Cytoplasm Antibody-Associated Vasculitides.
Lin M; Anesi SD; Ma L; Ahmed A; Small K; Foster CS
Am J Ophthalmol; 2018 Mar; 187():21-33. PubMed ID: 29258731
[TBL] [Abstract][Full Text] [Related]
23. Checkpoint inhibitor-related renal vasculitis and use of rituximab.
Mamlouk O; Lin JS; Abdelrahim M; Tchakarov AS; Glass WF; Selamet U; Buni M; Abdel-Wahab N; Abudayyeh A
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32718987
[TBL] [Abstract][Full Text] [Related]
24. Response to: 'Correspondence on 'Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis'' by Parikh
Smith RM; Merkel PA; Jayne D
Ann Rheum Dis; 2023 Jan; 82(1):e24. PubMed ID: 33542105
[No Abstract] [Full Text] [Related]
25. Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Jain S; Chattopadhyay A; Sharma A
Ann Intern Med; 2020 Dec; 173(11):947. PubMed ID: 33253614
[No Abstract] [Full Text] [Related]
26. Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Garvey TD; Warrington KJ; Koster MJ
Ann Intern Med; 2020 Dec; 173(11):947-948. PubMed ID: 33253612
[No Abstract] [Full Text] [Related]
27. Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Charles P; Guillevin L
Ann Intern Med; 2020 Dec; 173(11):948. PubMed ID: 33253611
[No Abstract] [Full Text] [Related]
28. A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis.
Arnold J; Vital EM; Dass S; Aslam A; Rawstron AC; Savic S; Emery P; Md Yusof MY
Front Immunol; 2021; 12():803175. PubMed ID: 35095887
[TBL] [Abstract][Full Text] [Related]
29. Development and Validation of a Simulation Model for Treatment to Maintain Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Wallace ZS; Stone JH; Fu X; Merkel PA; Miloslavsky EM; Zhang Y; Choi HK; Hyle EP
Arthritis Care Res (Hoboken); 2023 Sep; 75(9):1976-1985. PubMed ID: 36645017
[TBL] [Abstract][Full Text] [Related]
30. Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis.
Gulati K; Edwards H; Prendecki M; Cairns TD; Condon M; Galliford J; Griffith M; Levy JB; Tam FWK; Tanna A; Pusey CD; McAdoo SP
Kidney Int; 2021 Dec; 100(6):1316-1324. PubMed ID: 34560140
[TBL] [Abstract][Full Text] [Related]
31. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
Smith RM; Jones RB; Guerry MJ; Laurino S; Catapano F; Chaudhry A; Smith KG; Jayne DR
Arthritis Rheum; 2012 Nov; 64(11):3760-9. PubMed ID: 22729997
[TBL] [Abstract][Full Text] [Related]
32. Biomarkers in vasculitis.
Hatemi G; Esatoglu SN; Yazici Y
Curr Opin Rheumatol; 2018 Jan; 30(1):30-35. PubMed ID: 28937415
[TBL] [Abstract][Full Text] [Related]
33. Unsolved questions and concerns about treatment of anti-neutrophil cytoplasm antibody-associated vasculitides.
Chaigne B; Guillevin L
Clin Exp Rheumatol; 2016; 34(3 Suppl 97):S121-8. PubMed ID: 27087528
[TBL] [Abstract][Full Text] [Related]
34. [Recent advances in the treatment of antineutrophil cytoplasm antibody associated vasculitides].
Szabó MZ; Pálfi P; Bazsó A; Poór G; Kiss E
Orv Hetil; 2015 Oct; 156(41):1653-60. PubMed ID: 26551168
[TBL] [Abstract][Full Text] [Related]
35. Association between renal-limited vasculitis and relapse of antineutrophil cytoplasmic antibody-associated vasculitis: A single-center retrospective cohort study in Japan.
Yamaguchi M; Ito M; Sugiyama H; Iwagaitsu S; Nobata H; Kinashi H; Katsuno T; Ando M; Kubo Y; Banno S; Ito Y; Ishimoto T
PLoS One; 2022; 17(9):e0274483. PubMed ID: 36174007
[TBL] [Abstract][Full Text] [Related]
36. Recurrence of ANCA-associated vasculitis in a patient with kidney trasplant.
García Cosmes P; Fraile Gómez P; Lewczuk K; Rodríguez González M; Ruiz Ferreras E; Tabernero Fernández G
Nefrologia; 2016; 36(2):176-80. PubMed ID: 26850517
[TBL] [Abstract][Full Text] [Related]
37. [ANCA vasculitis preceded by isolated joint manifestations. Report of two cases and literature review].
Brevet P; Curie A; Princivil C; Zarnitsky C; Alcaix D
Rev Med Interne; 2021 Sep; 42(9):650-653. PubMed ID: 34147260
[TBL] [Abstract][Full Text] [Related]
38. Treating Patients With ANCA-Associated Vasculitis and Very Severe Renal Injury With an Intensified B Cell Depletion Therapy: Comparison With a Control Cohort Receiving a Conventional Therapy.
Roccatello D; Sciascia S; Murgia S; Quattrocchio G; Ferro M; De Simone E; Naretto C; Barreca A; Sammartino A; Rossi D; Fenoglio R
Front Immunol; 2022; 13():777134. PubMed ID: 35401565
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of low-dose rituximab as induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement: a Chinese case series.
Liu L; Lu H; Zou G; Wang H; Li J; Yang Y; Zhang J; Wang X; Li W; Zhuo L
BMC Nephrol; 2023 Feb; 24(1):28. PubMed ID: 36755215
[TBL] [Abstract][Full Text] [Related]
40. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Terrier B; Pagnoux C; Perrodeau É; Karras A; Khouatra C; Aumaître O; Cohen P; Decaux O; Desmurs-Clavel H; Maurier F; Gobert P; Quémeneur T; Blanchard-Delaunay C; Bonnotte B; Carron PL; Daugas E; Ducret M; Godmer P; Hamidou M; Lidove O; Limal N; Puéchal X; Mouthon L; Ravaud P; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1150-1156. PubMed ID: 29724729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
